Opinion|Videos|May 12, 2025
The Impact of Tumor Heterogeneity in Ovarian Cancer
Author(s)Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Impact of Tumor Heterogeneity on Testing Reliability
Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, considerations include the following:
- More recent biopsies are preferred for testing when available.
- Blood-based testing (liquid biopsies) can provide genomic information by sampling circulating tumor DNA from the entire tumor burden.
- Cell-free DNA testing is increasingly useful but cannot yet replace tissue-based testing for protein expression markers like HER2 and folate receptor alpha.
Research continues to develop more comprehensive testing through liquid biopsy approaches.
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5